Procter & Gamble Health share news, announcements and annual reports
NSE: PGHLBSE: 500126Pharmaceuticals & BiotechnologySmall Cap
Procter & Gamble Health Limited · Formerly Merck · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1982 on BSE, Apr 1996 on NSE
Last close ₹5,670.50up ₹157.00 (2.85%)BSE ₹5,684.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹5,513.50.
30 Oct: open ₹5,501.50, high ₹5,731.00, low ₹5,442.50
52-week range of traded prices to 30 Oct 2026
₹4,707.00Low, 6 Apr 2026₹6,975.00High, 15 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,413 Cr585th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.37
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 17.94
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 3.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 67.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 13,61957.6% delivered
Procter & Gamble Health disputes and clarifications
13 filed, newest first.
Apr 2020
9 Apr · Legal
The exchange asked on 8 Apr 2020
Mar 2019
Aug 2018
8 Aug · Legal
Exchange has sought clarification from the Company with respect to news item captioned- CCI approves P&G's stake acquisition in Merck In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
May 2018
31 May · Legal
The exchange asked on 30 May 2018
Apr 2018
20 Apr · Legal
Exchange has sought clarification from Merck Limited with respect to announcement dated 19-Apr-2018, regarding " Merck Limited has informed the Exchange regarding a press release dated April 19, 2018, titled "Merck to Sell Consumer Health to Procter & Gamble".". On basis of above the Company is required to clarify following: 1. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale. 2. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"; The response of the Company is awaited.
Jan 2018
16 Jan · Legal
The exchange asked on 15 Jan 2018
Dec 2016
23 Dec · Legal
Exchange has sought clarification from Merck Limited with respect to announcement dated 23-Dec-2016, informing that Ms. Zoe Tang has been appointed as Non- Executive Director of the Company effective December 23, 2016.On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
Oct 2016
5 Oct · Legal
Exchange has sought clarification from Merck Limited with respect to announcement dated 04-Oct-2016, informing that "Due to certain organisation changes at Merck which impacted the roles and responsibilities of two whole time directors viz. Mr. Brijesh Kapil and Mr. Ali Sleiman. As such M/s Brijesh Kapil & Ali Sleiman have expressed their inability to continue as directors on the Board and have tendered their resignations from the office of director w.e.f 04 October 2016. Additionally, ultimate holding company Merck KGaA, Germany has changed the nomination of non -executive director, Mr. Bradley Simpson and in his place has appointed Ms. Zoe Tang, Regional CFO Central Asia as member of the Board".On basis of above the Company is required to clarify following:1. Date of appointment/cessation (as applicable) & term of appointment;2. Brief profile (in case of appointment);3. Dsclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
Mar 2016